731 related articles for article (PubMed ID: 18408733)
21. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus.
Müller S; Matunis MJ; Dejean A
EMBO J; 1998 Jan; 17(1):61-70. PubMed ID: 9427741
[TBL] [Abstract][Full Text] [Related]
22. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Isakson P; Bjørås M; Bøe SO; Simonsen A
Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
[TBL] [Abstract][Full Text] [Related]
23. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H
J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191
[TBL] [Abstract][Full Text] [Related]
24. PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
Jo S; Lee YL; Kim S; Lee H; Chung H
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1499-509. PubMed ID: 27030546
[TBL] [Abstract][Full Text] [Related]
25. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML.
Weisshaar SR; Keusekotten K; Krause A; Horst C; Springer HM; Göttsche K; Dohmen RJ; Praefcke GJ
FEBS Lett; 2008 Sep; 582(21-22):3174-8. PubMed ID: 18708055
[TBL] [Abstract][Full Text] [Related]
26. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
[TBL] [Abstract][Full Text] [Related]
27. Arkadia, a novel SUMO-targeted ubiquitin ligase involved in PML degradation.
Erker Y; Neyret-Kahn H; Seeler JS; Dejean A; Atfi A; Levy L
Mol Cell Biol; 2013 Jun; 33(11):2163-77. PubMed ID: 23530056
[TBL] [Abstract][Full Text] [Related]
28. Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
Janssen K; Hofmann TG; Jans DA; Hay RT; Schulze-Osthoff K; Fischer U
Oncogene; 2007 Mar; 26(11):1557-66. PubMed ID: 16924230
[TBL] [Abstract][Full Text] [Related]
29. An arginine-rich motif of ring finger protein 4 (RNF4) oversees the recruitment and degradation of the phosphorylated and SUMOylated Krüppel-associated box domain-associated protein 1 (KAP1)/TRIM28 protein during genotoxic stress.
Kuo CY; Li X; Kong XQ; Luo C; Chang CC; Chung Y; Shih HM; Li KK; Ann DK
J Biol Chem; 2014 Jul; 289(30):20757-72. PubMed ID: 24907272
[TBL] [Abstract][Full Text] [Related]
30. Dynamics of component exchange at PML nuclear bodies.
Weidtkamp-Peters S; Lenser T; Negorev D; Gerstner N; Hofmann TG; Schwanitz G; Hoischen C; Maul G; Dittrich P; Hemmerich P
J Cell Sci; 2008 Aug; 121(Pt 16):2731-43. PubMed ID: 18664490
[TBL] [Abstract][Full Text] [Related]
31. Marked for death.
Petrie K; Zelent A
Nat Cell Biol; 2008 May; 10(5):507-9. PubMed ID: 18454129
[No Abstract] [Full Text] [Related]
32. The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA.
Jaffray EG; Tatham MH; Mojsa B; Liczmanska M; Rojas-Fernandez A; Yin Y; Ball G; Hay RT
J Cell Biol; 2023 Apr; 222(4):. PubMed ID: 36880596
[TBL] [Abstract][Full Text] [Related]
33. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
[TBL] [Abstract][Full Text] [Related]
34. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
35. The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.
Andre C; Guillemin MC; Zhu J; Koken MH; Quignon F; Herve L; Chelbi-Alix MK; Dhumeaux D; Wang ZY; Degos L; Chen Z; de The H
Exp Cell Res; 1996 Dec; 229(2):253-60. PubMed ID: 8986606
[TBL] [Abstract][Full Text] [Related]
36. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
37. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
38. ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator.
Karvonen U; Jääskeläinen T; Rytinki M; Kaikkonen S; Palvimo JJ
J Mol Biol; 2008 Oct; 382(3):585-600. PubMed ID: 18656483
[TBL] [Abstract][Full Text] [Related]
39. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.
Grignani F; Testa U; Rogaia D; Ferrucci PF; Samoggia P; Pinto A; Aldinucci D; Gelmetti V; Fagioli M; Alcalay M; Seeler J; Grignani F; Nicoletti I; Peschle C; Pelicci PG
EMBO J; 1996 Sep; 15(18):4949-58. PubMed ID: 8890168
[TBL] [Abstract][Full Text] [Related]
40. Manipulating PML SUMOylation via Silencing UBC9 and RNF4 Regulates Cardiac Fibrosis.
Liu Y; Zhao D; Qiu F; Zhang LL; Liu SK; Li YY; Liu MT; Wu D; Wang JX; Ding XQ; Liu YX; Dong CJ; Shao XQ; Yang BF; Chu WF
Mol Ther; 2017 Mar; 25(3):666-678. PubMed ID: 28143738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
